@Here_4_Sports@biotechlearner@biomannn more of a concern in SM the smaller indication for Bezu, 2L gist shouldn't matter anyway... sunitinib has black box
@biotechlearner@Here_4_Sports@biomannn most likely label outcome is no box but explicit hepatotoxicity monitoring/dose modification warning... maybe 20% odds of black box?
JENSEN HUANG: “We don't welcome political discourse inside our company. Take it home … We're bipartisan. We want America to succeed … The discourse about race and religion and politics and all of that stuff, we tell people do it outside the company. It's not for us.”
@Dumbhead62@A_May_MD@adamfeuerstein who cares if they realize the true value though is my point. just sell it after crohn's if it hits for likely more than it would sell for prior to that. I think best case scenario would be a deal now thru JPM plus a CVR for crohn's for those who want to play that readout
@A_May_MD@Dumbhead62@adamfeuerstein "I'm nervous it may go to $300 if crohn's hits... it'd then be too big to buy. I would much rather it get bought for $200.
@biofeed damnit. for some reason I'm envisioning them just boiling stuff in a big bowl of water with other stuff (stew) . they probably do some unreal wild boar roasts on the spit.